OMRIX Phase 3 Human Thrombin Trial Results Positive
OMRIX Biopharmaceuticals (OMRI) announced today that its phae 3 clinical trials for human derived thrombin met all endpoints.
Thrombin can be used for hemostasis and surgical wound repair. OMRIX's thrombin is human derived and contains no animal products, and is thought to potentially have less side effects and immune response. Thermogenesis is currently developing and marketing autologous thrombin, from patient's own blood, that could eliminate the immune response.
Shares of OMRIX jumped about 10% on October 11 after the company announced it had entered into a supply agreement with Talecris Biotherapeutics, from which OMRIX will acquire raw materials necessary for BAC, a key component of its fibrin sealnt products.
Look for shares of OMRIX to open trading strong on Monday following its positive phase 3 news.
OMRIX Biopharmaceuticals (OMRI) announced today that its phae 3 clinical trials for human derived thrombin met all endpoints.
Thrombin can be used for hemostasis and surgical wound repair. OMRIX's thrombin is human derived and contains no animal products, and is thought to potentially have less side effects and immune response. Thermogenesis is currently developing and marketing autologous thrombin, from patient's own blood, that could eliminate the immune response.
Shares of OMRIX jumped about 10% on October 11 after the company announced it had entered into a supply agreement with Talecris Biotherapeutics, from which OMRIX will acquire raw materials necessary for BAC, a key component of its fibrin sealnt products.
Look for shares of OMRIX to open trading strong on Monday following its positive phase 3 news.
posted by Nico at
7:35 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home